USFDA Issues Form 483 To Biocon's Malaysia Insulin Facility
  • WebDesk BTVI
  • Jul 10 2019

USFDA has issued Form 483 to Biocon's insulin facility in Malaysia, inspections across 3 units of facility resulted in 12 observations. FDA had also issued a CRL in June 2018 for the company's insulin glargine.